A detailed history of Vanguard Group Inc transactions in Cabaletta Bio, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 2,276,222 shares of CABA stock, worth $16.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,276,222
Previous 2,131,931 6.77%
Holding current value
$16.4 Million
Previous $48.4 Million 19.76%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$16.79 - $25.38 $2.42 Million - $3.66 Million
144,291 Added 6.77%
2,276,222 $38.8 Million
Q4 2023

Feb 14, 2024

BUY
$12.21 - $23.36 $2 Million - $3.83 Million
163,823 Added 8.32%
2,131,931 $48.4 Million
Q3 2023

Nov 14, 2023

BUY
$11.84 - $18.65 $2.92 Million - $4.6 Million
246,596 Added 14.32%
1,968,108 $30 Million
Q2 2023

Aug 14, 2023

BUY
$7.65 - $13.95 $4.65 Million - $8.48 Million
607,569 Added 54.54%
1,721,512 $22.2 Million
Q1 2023

May 15, 2023

BUY
$7.08 - $12.62 $1.31 Million - $2.33 Million
184,754 Added 19.88%
1,113,943 $9.21 Million
Q4 2022

Feb 10, 2023

SELL
$1.76 - $9.3 $614,877 - $3.25 Million
-349,362 Reduced 27.32%
929,189 $8.59 Million
Q3 2022

Nov 14, 2022

BUY
$0.63 - $2.05 $142,829 - $464,761
226,713 Added 21.55%
1,278,551 $831,000
Q1 2022

May 13, 2022

BUY
$1.68 - $3.92 $247,541 - $577,596
147,346 Added 16.29%
1,051,838 $2.14 Million
Q4 2021

Feb 14, 2022

BUY
$3.36 - $14.64 $583,668 - $2.54 Million
173,711 Added 23.77%
904,492 $3.43 Million
Q3 2021

Nov 12, 2021

BUY
$7.0 - $12.5 $4,074 - $7,275
582 Added 0.08%
730,781 $8.89 Million
Q2 2021

Aug 13, 2021

BUY
$7.2 - $11.73 $5.26 Million - $8.57 Million
730,199 New
730,199 $6.28 Million

Others Institutions Holding CABA

About Cabaletta Bio, Inc.


  • Ticker CABA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,014,000
  • Market Cap $209M
  • Description
  • Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce di...
More about CABA
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.